Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Celergen is an **oral dietary supplement** described as the "first cell therapy supplement" formulated in Switzerland for anti-aging and regenerative health benefits. The main active ingredient is a patented **BioDNA Cellular Marine Complex**, derived from **marine (deep-sea salmon and herring) DNA and peptides**, and formulated with additional ingredients including **hydrolyzed collagen peptides (Peptide E Collagen), marine peptides, natural lutein, coenzyme Q10, and selenium**. Celergen claims mechanisms including antioxidative, anti-inflammatory, and immune-modulatory effects, supporting cell repair, rejuvenation, and protection against oxidative stress. It is not a pharmaceutical but is rather classified as a high-risk food supplement with no approved therapeutic claims. It is primarily indicated as an anti-aging formula, with studies reporting benefits in joint pain, asthenia (fatigue), fibromyalgia, skin aging, bone health, and general well-being, but it is not approved for any disease treatment or prevention and lacks established pharmacological targets[1][2][3][4][5][7][8][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Celergen.